Recurrent hepatitis C post-transplantation: Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop

Kymberly D S Watt, Kelly Burak, Marc Deshênes, Les Lilly, Denis Marleau, Paul Marotta, Andrew Mason, Kevork M. Peltekian, Eberhard L. Renner, Eric M. Yoshida

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Approximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45% of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural history, new complication risks and different treatment efficacy than nontransplant HCV patients. Every effort must be made to identify those patients at highest risk for progressive liver disease post-transplant. Recurrent HCV is an Achilles' heel to transplant hepatology. The true natural history of this disease is only starting to unravel and many questions remain unanswered on the optimal management of these patients after liver transplantation. The present report summarizes the literature and ongoing research needs that are specific to HCV-related liver transplantation.

Original languageEnglish (US)
Pages (from-to)725-734
Number of pages10
JournalCanadian Journal of Gastroenterology
Volume20
Issue number11
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Gastroenterology
Hepatitis C
Transplantation
Hepacivirus
Transplants
Education
Liver Transplantation
Liver Diseases
Liver
Natural History
Canada
Research

Keywords

  • Management
  • Recurrent heaptitis C
  • Research
  • Risk factors
  • Transplantation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Watt, K. D. S., Burak, K., Deshênes, M., Lilly, L., Marleau, D., Marotta, P., ... Yoshida, E. M. (2006). Recurrent hepatitis C post-transplantation: Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Canadian Journal of Gastroenterology, 20(11), 725-734.

Recurrent hepatitis C post-transplantation : Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. / Watt, Kymberly D S; Burak, Kelly; Deshênes, Marc; Lilly, Les; Marleau, Denis; Marotta, Paul; Mason, Andrew; Peltekian, Kevork M.; Renner, Eberhard L.; Yoshida, Eric M.

In: Canadian Journal of Gastroenterology, Vol. 20, No. 11, 11.2006, p. 725-734.

Research output: Contribution to journalArticle

Watt, KDS, Burak, K, Deshênes, M, Lilly, L, Marleau, D, Marotta, P, Mason, A, Peltekian, KM, Renner, EL & Yoshida, EM 2006, 'Recurrent hepatitis C post-transplantation: Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop', Canadian Journal of Gastroenterology, vol. 20, no. 11, pp. 725-734.
Watt, Kymberly D S ; Burak, Kelly ; Deshênes, Marc ; Lilly, Les ; Marleau, Denis ; Marotta, Paul ; Mason, Andrew ; Peltekian, Kevork M. ; Renner, Eberhard L. ; Yoshida, Eric M. / Recurrent hepatitis C post-transplantation : Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. In: Canadian Journal of Gastroenterology. 2006 ; Vol. 20, No. 11. pp. 725-734.
@article{06fa99eab6824621bed7a055bf61d0f8,
title = "Recurrent hepatitis C post-transplantation: Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop",
abstract = "Approximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45{\%} of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural history, new complication risks and different treatment efficacy than nontransplant HCV patients. Every effort must be made to identify those patients at highest risk for progressive liver disease post-transplant. Recurrent HCV is an Achilles' heel to transplant hepatology. The true natural history of this disease is only starting to unravel and many questions remain unanswered on the optimal management of these patients after liver transplantation. The present report summarizes the literature and ongoing research needs that are specific to HCV-related liver transplantation.",
keywords = "Management, Recurrent heaptitis C, Research, Risk factors, Transplantation",
author = "Watt, {Kymberly D S} and Kelly Burak and Marc Desh{\^e}nes and Les Lilly and Denis Marleau and Paul Marotta and Andrew Mason and Peltekian, {Kevork M.} and Renner, {Eberhard L.} and Yoshida, {Eric M.}",
year = "2006",
month = "11",
language = "English (US)",
volume = "20",
pages = "725--734",
journal = "Canadian Journal of Gastroenterology and Hepatology",
issn = "2291-2789",
publisher = "Pulsus Group Inc.",
number = "11",

}

TY - JOUR

T1 - Recurrent hepatitis C post-transplantation

T2 - Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop

AU - Watt, Kymberly D S

AU - Burak, Kelly

AU - Deshênes, Marc

AU - Lilly, Les

AU - Marleau, Denis

AU - Marotta, Paul

AU - Mason, Andrew

AU - Peltekian, Kevork M.

AU - Renner, Eberhard L.

AU - Yoshida, Eric M.

PY - 2006/11

Y1 - 2006/11

N2 - Approximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45% of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural history, new complication risks and different treatment efficacy than nontransplant HCV patients. Every effort must be made to identify those patients at highest risk for progressive liver disease post-transplant. Recurrent HCV is an Achilles' heel to transplant hepatology. The true natural history of this disease is only starting to unravel and many questions remain unanswered on the optimal management of these patients after liver transplantation. The present report summarizes the literature and ongoing research needs that are specific to HCV-related liver transplantation.

AB - Approximately 400 liver transplants are performed in Canada every year and close to 6000 per year in the United States. Forty per cent to 45% of all liver transplants are performed for patients with underlying hepatitis C virus (HCV)-related liver disease. These patients have a different natural history, new complication risks and different treatment efficacy than nontransplant HCV patients. Every effort must be made to identify those patients at highest risk for progressive liver disease post-transplant. Recurrent HCV is an Achilles' heel to transplant hepatology. The true natural history of this disease is only starting to unravel and many questions remain unanswered on the optimal management of these patients after liver transplantation. The present report summarizes the literature and ongoing research needs that are specific to HCV-related liver transplantation.

KW - Management

KW - Recurrent heaptitis C

KW - Research

KW - Risk factors

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=33845659868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845659868&partnerID=8YFLogxK

M3 - Article

C2 - 17111055

AN - SCOPUS:33845659868

VL - 20

SP - 725

EP - 734

JO - Canadian Journal of Gastroenterology and Hepatology

JF - Canadian Journal of Gastroenterology and Hepatology

SN - 2291-2789

IS - 11

ER -